skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Datamonitor Healthcare attended the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place between 6 December and 9 December 2014, in San Francisco, California.

 

 

Datamonitor Healthcare has identified the following key highlights from the meeting:

Data from Phase I and Phase II trials investigating several therapies based on chimeric antigen receptor T-cells (CAR-Ts) indicated promising efficacy for this class of therapies in the treatment of various B-cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL).

 

Monoclonal antibodies (MAbs) continue to advance in pipeline development for multiple myeloma (MM).

 

 

 

ASH-2014

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: